abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
EBITDA Margin
234.72%
TTM · Period ending:
HQL EBITDA Margin
Latest reported234.72%period ending
Latest reported234.72%period ending
HQL TTM EBITDA Margin (5000.00% → 234.72%)
TTM ebitda margin
High-resolution chart · PNG
HQL ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| 234.7234% | |
| 660.043% | |
| 154.8702% | |
| 355.1768% | |
| 115.7449% | |
| -176.5086% | |
| -133.6634% | |
| -42.8619% | |
| 123.5717% | |
| 230.5373% | |
| 228.6931% | |
| 301.5469% | |
| 117.892% | |
| 0% | |
| 0% | |
| -0.0001% | |
| -0.0002% | |
| -0.0321% | |
| -0.0653% | |
| -0.0362% | |
| 0% | |
| -0.0909% | |
| 3,673.0382% | |
| 5,813.7582% | |
| 1,625.5413% | |
| 3,682.5727% | |
| 4,019.6442% | |
| 4,287.4673% | |
| 4,515.8835% | |
| 1,994.1423% | |
| 1,171.3062% | |
| 308.7719% | |
| 1,454.4218% | |
| 2,680.7512% | |
| 2,512.8743% | |
| 2,434.2857% | |
| 1,643.6793% | |
| 949.2278% | |
| 1,106.2127% | |
| 1,361.1285% | |
| 2,166.8182% | |
| 4,290.9091% | |
| 4,565.4206% | |
| 4,922.5806% | |
| 3,301.6129% | |
| 2,329.0323% | |
| 742.723% | |
| -164.5756% | |
| -176.4069% | |
| -193.1937% | |
| 411.3924% | |
| 2,921.7391% | |
| 4,203.3333% | |
| 5,000% |